ABSTRACT
Secondary surgeries for single craniosynostosis surgeries are mainly esthetic refinements rather than functional indications. However, cranioplasties for bone defects correction or insufficient corrections may be undertaken. Management of syndromic craniosynostoses usually requires multiple surgical interventions, the sequence of which might vary per the genetic mutation. It is commonplace to start with posterior vault expansion before age 6 months, then treat cerebellar tonsillar herniation by the age of twelve months, and delay fronto-facial monobloc advancement until at least 18-24 months of age. Ventricular shunting is preferably avoided or delayed. Failure to respect these guidelines can significantly complicate the subsequent management. Primary fronto-orbital advancement or early facial osteotomy type Le Fort3, may compromise the subsequent fronto-facial monobloc advancement. However, this salvage secondary monobloc may be undertaken in some instances despite previous anterior osteotomies with a higher morbidity.
Subject(s)
Craniofacial Dysostosis/surgery , Craniosynostoses/surgery , Plastic Surgery Procedures/methods , Reoperation , Adolescent , Child , Child, Preschool , Humans , InfantABSTRACT
The complexity of treatment of faciocraniosynostosis justifies the treatment in a reference center for rare diseases. The growth disturbances in the skull and face being variable according to the type of mutation in the FGFr (Crouzon, Pfeiffer, Apert), the strategy is adapted to the phenotype according to the following principles: posterior expansion with or without distraction around 6 months to limit the descent of the cerebellum tonsils and to prevent the turricephalic development; fronto-facial monobloc advancement with internal distraction around the age of 18 months in case of severe exorbitism or breathing impairment. The dissociated strategy (fronto-orbital advancement first, followed by facial osteotomy of Le Fort 3 type). The growing evolution dictates the sequence of subsequent surgeries according to the monitoring of intracranial pressure by fundus examination and of the respiration by polysomnography. Le Fort 3 and transversal maxillary distraction may be repeated if necessary. Orthognathic surgery is almost always compulsory after the age of 14, before the aesthetic refinements which can be undertaken ultimately (rhinoplasty, genioplasty, canthopexies, fat grafting ).
Subject(s)
Craniofacial Dysostosis/surgery , Craniosynostoses/surgery , Plastic Surgery Procedures/methods , Child , Craniofacial Dysostosis/diagnostic imaging , Craniosynostoses/diagnostic imaging , Craniotomy , Humans , Imaging, Three-Dimensional , Osteogenesis, Distraction , Surgery, Computer-AssistedABSTRACT
Copper and nickel nanoparticles were synthesized using reducing agents in the presence of direct high energy ultra-sonication. The metallic nanoparticles were decorated on various ceramic substrates (e.g. α-Al2O3, and TiO2) leading to metal reinforced ceramics with up to 45% metallic content. Different parameters, such as the amount of precursor material or the substrate, as well as the intensity of ultrasound were examined, in order to evaluate the percentage of final metallic decoration on the composite materials. All products were characterized by means of Inductively Coupled Plasma Spectroscopy in order to investigate the loading with metallic particles. X-ray Diffraction and Scanning Electron Microscopy were also used for further sample characterization. Selected samples were examined using Transmission Electron Microscopy, while finally, some of the powders synthesized, were densified by means of Spark Plasma Sintering, followed by a SEM/EDX examination and an estimation of their porosity.
ABSTRACT
The pineal gland secretes melatonin (MLT) that circulates in the blood and cerebrospinal fluid (CSF). We provide data to support the hypothesis that, in sheep and possibly in humans, only the CSF MLT, and not the blood MLT, can provide most of MLT to the cerebral tissue in high concentrations, particularly in the periventricular area. The MLT content of sheep brain, our chosen animal model, was found in significant concentration gradients oriented from the ventricle (close to the CSF) to the cerebral tissue, with concentrations varying by a factor of 1-125. The highest concentrations were observed close to the ventricle wall, whereas the lowest concentrations were furthest from the ventricles (407.0 ± 71.5 pg/ml compared to 84.7 ± 5.2 pg/ml around the third ventricle). This concentration gradient was measured in brain tissue collected at mid-day and at the end of the night. Nocturnal concentrations were higher than daytime concentrations, reflecting the diurnal variation in the pineal gland. The concentration gradient was not detected when MLT was delivered to the brain via the bloodstream. The diffusion of MLT to cerebral tissues via CSF was supported by in vivo scintigraphy and autoradiography. 2-[(123)I]-MLT infused into the CSF quickly and efficiently diffused into the brain tissues, whereas [(123)I]-iodine (control) was mostly washed away by the CSF flow and [(123)I]-bovine serum albumin remained mostly in the CSF. Taken together, these data support a critical role of CSF in providing the brain with MLT.
Subject(s)
Brain/metabolism , Melatonin/metabolism , Sheep/physiology , Animals , Blood-Brain Barrier , Female , Melatonin/blood , Melatonin/cerebrospinal fluid , Radionuclide ImagingABSTRACT
BACKGROUND: Surgery of limited metastatic lesions from malignant melanoma can achieve long-term remission and better survival than chemotherapy. Existing criteria for selection of candidate patients for this surgery do not seem sufficient to avoid useless excisions. OBJECTIVES: To test use of neoadjuvant chemotherapy as a new criterion in this setting. METHODS: All patients who underwent thoracic surgery for one or two lung metastases from melanoma during 1999-2007 were included in the study. Demographic and medical data were collected and analysed. Several possible prognostic factors were evaluated based on the overall survival curves. RESULTS: Thirteen patients were included in this retrospective study. All but two patients had no evidence of disease after surgery. Ten patients received neoadjuvant chemotherapy. Six responded (absence of progression) and four had progressive disease. Response to chemotherapy and no evidence of disease after surgery were predictive of long-term survival. CONCLUSIONS: Neoadjuvant chemotherapy can be considered as a new criterion for better selection of candidate patients for lung metastasis surgical resection. This would also avoid useless surgical procedures in rapidly progressive disease and give information on the chemosensibility of the metastatic disease. This study needs further confirmation, particularly with chemotherapy regimens that have demonstrated better objective responses.
Subject(s)
Lung Neoplasms/surgery , Melanoma/surgery , Neoadjuvant Therapy/methods , Adult , Aged , Chemotherapy, Adjuvant/methods , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Male , Melanoma/drug therapy , Melanoma/secondary , Middle Aged , Patient Selection , Prognosis , Retrospective Studies , Survival Analysis , Treatment OutcomeABSTRACT
BACKGROUND AND PURPOSE: For many years, it was suspected that sheep expressed only one melatonin receptor (closely resembling MT(1) from other mammal species). Here we report the cloning of another melatonin receptor, MT(2), from sheep. EXPERIMENTAL APPROACH: Using a thermo-resistant reverse transcriptase and polymerase chain reaction primer set homologous to the bovine MT(2) mRNA sequence, we have cloned and characterized MT(2) receptors from sheep retina. KEY RESULTS: The ovine MT(2) receptor presents 96%, 72% and 67% identity with cattle, human and rat respectively. This MT(2) receptor stably expressed in CHO-K1 cells showed high-affinity 2[(125)I]-iodomelatonin binding (K(D)= 0.04 nM). The rank order of inhibition of 2[(125)I]-iodomelatonin binding by melatonin, 4-phenyl-2-propionamidotetralin and luzindole was similar to that exhibited by MT(2) receptors of other species (melatonin > 4-phenyl-2-propionamidotetralin > luzindole). However, its pharmacological profile was closer to that of rat, rather than human MT(2) receptors. Functionally, the ovine MT(2) receptors were coupled to G(i) proteins leading to inhibition of adenylyl cyclase, as the other melatonin receptors. In sheep brain, MT(2) mRNA was expressed in pars tuberalis, choroid plexus and retina, and moderately in mammillary bodies. Real-time polymerase chain reaction showed that in sheep pars tuberalis, premammillary hypothalamus and mammillary bodies, the temporal pattern of expression of MT(1) and MT(2) mRNA was not parallel in the three tissues. CONCLUSION AND IMPLICATIONS: Co-expression of MT(1) and MT(2) receptors in all analysed sheep brain tissues suggests that MT(2) receptors may participate in melatonin regulation of seasonal anovulatory activity in ewes by modulating MT(1) receptor action.
Subject(s)
Receptor, Melatonin, MT2/genetics , Amino Acid Sequence , Animals , Brain/metabolism , CHO Cells , Cattle , Cloning, Molecular , Cricetinae , Cricetulus , Female , GTP-Binding Proteins/metabolism , Humans , Molecular Sequence Data , Organ Specificity , RNA, Messenger/metabolism , Radioligand Assay , Rats , Receptor, Melatonin, MT1/antagonists & inhibitors , Receptor, Melatonin, MT1/metabolism , Receptor, Melatonin, MT2/antagonists & inhibitors , Receptor, Melatonin, MT2/metabolism , Recombinant Proteins/metabolism , Retina/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Sheep , Tetrahydronaphthalenes/pharmacology , Tryptamines/pharmacologyABSTRACT
In the eel, a deficit in gonadotrophin-releasing hormone (GnRH) and a strong dopaminergic (DA) inhibition are responsible for the blockade of gonad development if silver eels are prevented from their reproductive migration. Environmental factors that eels encounter during their oceanic reproductive migration are thought to play an important role in the stimulation of eel pubertal development. We investigated the potential role of melatonin, a known mediator of the effects of external factors on reproductive function in vertebrates. We demonstrated that a long-term melatonin treatment increased brain tyrosine hydroxylase (TH, the rate limiting enzyme of DA synthesis) mRNA expression in a region-dependent way. Melatonin stimulated the dopaminergic system of the preoptic area, which is involved in the inhibitory control of gonadotrophin [luteinising hormone (LH) and follicle-stimulating hormone (FSH)] synthesis and release. Moreover, we showed that the increased TH expression appeared to be consistent with melatonin binding site distribution as shown by 2[(125)I]-melatonin labelling studies. On the other hand, melatonin had no effects on the two eel native forms of GnRH (mGnRH and cGnRH-II) mRNA expression. Concerning the pituitary-gonad axis, we showed that melatonin treatment decreased both gonadotrophin beta-subunit (LHbeta, FSHbeta) mRNA expression and reduced sexual steroid (11-ketotestosterone, oestradiol) plasma levels. This indicates that melatonin treatment had a negative effect on eel reproductive function. To our knowledge, the results of the present study provide the first evidence that melatonin enhances TH expression in specific brain regions in a non-mammalian species. By this mechanism melatonin could represent one pathway by which environmental factors could modulate reproductive function in the eel.
Subject(s)
Brain/drug effects , Dopamine/metabolism , Eels/physiology , Melatonin/pharmacology , Reproduction/drug effects , Animals , Binding Sites , Brain/metabolism , Down-Regulation/drug effects , Eels/metabolism , Endocrine System/drug effects , Endocrine System/metabolism , Female , Follicle Stimulating Hormone/genetics , Follicle Stimulating Hormone/metabolism , Gene Expression/drug effects , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/genetics , Gonadotropin-Releasing Hormone/metabolism , Luteinizing Hormone/genetics , Luteinizing Hormone/metabolism , Melatonin/metabolism , Models, Biological , Reproduction/physiology , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolismABSTRACT
We report the use of recombinant scorpion toxins in the form of fusion proteins as antigens for immunisation in rabbits and mice: the aim was to produce in these animal models protective antisera against the most lethal alpha-type toxins in the venom from the North African scorpion Androctonus australis. The cDNAs encoding AaH I, AaH II and AaH III (the three major alpha-type toxins acting on voltage-sensitive sodium channels) were fused to the sequence encoding the maltose binding protein (MBP). The constructs (MBP-AaH I, MBP-AaH II, MBP-AaH I+II and MBP-AaH III) were expressed in Escherichia coli, and resulting fusion proteins were translocated to the periplasmic space. The recombinant fusion proteins were characterised and used as antigens to generate antibodies in rabbits. These antibodies raised specifically recognised their corresponding radiolabelled-toxin with affinities in the 0.1nM range. In vitro neutralisation assays indicated that 1ml of serum raised against a mixture of fusion proteins was able to neutralise 15 LD(50) of the toxic fraction (AaH-G50) purified from the crude venom by molecular filtration through Sephadex G50. In vivo, the fusion proteins induced a long-term protection in mice against the lethal effects of AaH-G50 or of the native toxins. Ten weeks after the beginning of the immunisation programme, mice were challenged with various toxins or AaH-G50 doses. Mice were fully protected against three LD(50) of AaH-G50. Our work shows that fusion protein constructs can be used as a vaccine providing efficient immune protection against A. australis venom.
Subject(s)
Immunotherapy/methods , Scorpion Venoms/immunology , Scorpion Venoms/toxicity , Animals , Antibodies , Base Sequence , DNA, Complementary/genetics , Humans , Immunization , Mice , Neuropeptides/antagonists & inhibitors , Neuropeptides/genetics , Neuropeptides/immunology , Neuropeptides/toxicity , Neurotoxins/antagonists & inhibitors , Neurotoxins/genetics , Neurotoxins/immunology , Neurotoxins/toxicity , Neutralization Tests , Plasmids/genetics , Rabbits , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Reptilian Proteins , Scorpion Venoms/antagonists & inhibitors , Scorpion Venoms/genetics , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunologyABSTRACT
The full-length cDNA encoding the scorpion alpha-toxin Amm V was amplified from a cDNA library produced from the venom glands of the scorpion Androctonus mauretanicus mauretanicus from Morocco. We deduced the amino acid sequence of the encoded precursor protein and found that the mature toxin was similar to the previously characterised toxin. The genomic DNA sequence encoding the toxin was also amplified, subcloned and sequenced. This also led to the isolation of a new Amm V related-gene. Then, for the first time, we studied changes in the level of toxin mRNA synthesis over time.
Subject(s)
DNA/chemistry , Neurotoxins/toxicity , Peptides/toxicity , RNA, Messenger/biosynthesis , Scorpion Venoms/genetics , Scorpions/genetics , Type C Phospholipases/genetics , Amino Acid Sequence , Animals , Gene Amplification , Gene Library , Morocco , Neurotoxins/chemistry , Neurotoxins/isolation & purification , Peptides/chemistry , Peptides/isolation & purification , Polymerase Chain Reaction , Scorpion Venoms/chemistry , Sequence Alignment , Sequence Analysis, DNA , Time FactorsABSTRACT
A new scorpion toxin (3751.8 Da) was isolated from the Buthus martensi venom, sequenced and chemically synthesized (sBmTX3). The A-type current of striatum neurons in culture completely disappeared when 1 microM sBmTX3 was applied (Kd=54 nM), whereas the sustained K+ current was unaffected. 125I-sBmTX3 specifically bound to rat brain synaptosomes (maximum binding=14 fmol x mg(-1) of protein, Kd=0.21 nM). A panel of toxins yet described as specific ligands for K+ channels were unable to compete with 125I-sBmTX3. A high density of 125I-sBmTX3 binding sites was found in the striatum, hippocampus, superior colliculus, and cerebellum in the adult rat brain.
Subject(s)
Neostriatum/metabolism , Potassium Channel Blockers , Potassium Channels/metabolism , Scorpion Venoms/metabolism , Scorpion Venoms/pharmacology , Amino Acid Sequence , Animals , Autoradiography , Binding, Competitive , Cells, Cultured , Ion Channel Gating/drug effects , Molecular Sequence Data , Molecular Weight , Neostriatum/cytology , Neostriatum/drug effects , Neurotoxins/chemical synthesis , Neurotoxins/chemistry , Neurotoxins/metabolism , Neurotoxins/pharmacology , Patch-Clamp Techniques , Rats , Rats, Sprague-Dawley , Scorpion Venoms/chemical synthesis , Scorpion Venoms/chemistryABSTRACT
Maurotoxin (MTX) is a 34-residue toxin that has been isolated from the venom of the chactidae scorpion Scorpio maurus palmatus. The toxin displays an exceptionally wide range of pharmacological activity since it binds onto small conductance Ca(2+)-activated K(+) channels and also blocks Kv channels (Shaker, Kv1.2 and Kv1.3). MTX possesses 53-68% sequence identity with HsTx1 and Pi1, two other K(+) channel short chain scorpion toxins cross-linked by four disulfide bridges. These three toxins differ from other K(+)/Cl(-)/Na(+) channel scorpion toxins cross-linked by either three or four disulfide bridges by the presence of an extra half-cystine residue in the middle of a consensus sequence generally associated with the formation of an alpha/beta scaffold (an alpha-helix connected to an antiparallel beta-sheet by two disulfide bridges). Because MTX exhibits an uncommon disulfide bridge organization among known scorpion toxins (C1-C5, C2-C6, C3-C4, and C7-C8 instead of C1-C4, C2-C5, and C3-C6 for three-disulfide-bridged toxins or C1-C5, C2-C6, C3-C7, and C4-C8 for four-disulfide-bridged toxins), we designed and chemically synthesized an MTX analog with three instead of four disulfide bridges ([Abu(19),Abu(34)]MTX) and in which the entire consensus motif of scorpion toxins was restored by the substitution of the two half-cystines in positions 19 and 34 (corresponding to C4 and C8) by two isosteric alpha-aminobutyrate (Abu) derivatives. The three-dimensional structure of [Abu(19), Abu(34)]MTX in solution was solved by (1)H NMR. This analog adopts the alpha/beta scaffold with now conventional half-cystine pairings connecting C1-C5, C2-C6, and C3-C7 (with C4 and C8 replaced by Abu derivatives). This novel arrangement in half-cystine pairings that concerns the last disulfide bridge results mainly in a reorientation of the alpha-helix regarding the beta-sheet structure. In vivo, [Abu(19),Abu(34)]MTX remains lethal in mice as assessed by intracerebroventricular injection of the peptide (LD(50) value of 0. 25 microg/mouse). The structural variations are also accompanied by changes in the pharmacological selectivity of the peptide, suggesting that the organization pattern of disulfide bridges should affect the three-dimensional presentation of certain key residues critical to the blockage of K(+) channel subtypes.
Subject(s)
Drug Design , Scorpion Venoms/chemistry , Toxins, Biological/chemistry , Amino Acid Sequence , Animals , Disulfides , Magnetic Resonance Spectroscopy , Mice , Molecular Sequence Data , Protein Conformation , Scorpion Venoms/genetics , Scorpions , Toxins, Biological/chemical synthesis , Toxins, Biological/geneticsABSTRACT
The crystal structure of the bacterial K(+) channel, KcsA (Doyle, D. A., Morais, C. J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77), and subsequent mutagenesis have revealed a high structural conservation from bacteria to human (MacKinnon, R., Cohen, S. L., Kuo, A., Lee, A., and Chait, B. T. (1998) Science 280, 106-109). We have explored this conservation by swapping subregions of the M1-M2 linker of KcsA with those of the S5-S6 linker of the human Kv-channel Kv1.3. The chimeric K(+) channel constructs were expressed in Escherichia coli, and their multimeric state was analyzed after purification. We used two scorpion toxins, kaliotoxin and hongotoxin 1, which bind specifically to Kv1.3, to analyze the pharmacological properties of the KcsA-Kv1.3 chimeras. The results demonstrate that the high affinity scorpion toxin receptor of Kv1.3 could be transferred to KcsA. Our biochemical studies with purified KcsA-Kv1.3 chimeras provide direct chemical evidence that a tetrameric channel structure is necessary for forming a functional scorpion toxin receptor. We have obtained KcsA-Kv1.3 chimeras with kaliotoxin affinities (IC(50) values of approximately 4 pm) like native Kv1.3 channels. Furthermore, we show that a subregion of the S5-S6 linker may be an important determinant of the pharmacological profile of K(+) channels. Using available structural information on KcsA and kaliotoxin, we have developed a structural model for the complex between KcsA-Kv1.3 chimeras and kaliotoxin to aid future pharmacological studies of K(+) channels.
Subject(s)
Bacterial Proteins , Potassium Channels, Voltage-Gated , Potassium Channels/genetics , Recombinant Fusion Proteins/genetics , Sodium Channels/genetics , Amino Acid Sequence , Humans , Kv1.3 Potassium Channel , Molecular Sequence Data , Potassium Channels/chemistry , Potassium Channels/metabolism , Protein Binding , Recombinant Fusion Proteins/metabolism , Scorpion Venoms/metabolism , Sequence Homology, Amino Acid , Sodium Channels/metabolismABSTRACT
HpTX2 is a toxin from the venom of Heteropoda venatoria spider that has been demonstrated to bind on Kv4.2 potassium channel. We have determined the solution structure of recombinant HpTX2 by use of conventional two-dimensional NMR techniques followed by distance-geometry and molecular dynamics. The calculated structure belongs to the Inhibitory Cystin Knot structural family that consists in a compact disulfide-bonded core, from which four loops emerge. A poorly defined two-stranded antiparallel beta-sheet (residues 20-23 and 25-28) is detected. Analysis of the electrostatic charge anisotropy allows us to propose a functional map of HpTX2 different from the one described for kappa-conotoxin PVIIA, but strongly related to the one of charybdotoxin. The orientation of the dipole moment of HpTX2 emerges through K27 which could therefore be the critical lysine residue. Close to this lysine are a second basic residue, R23, an aromatic cluster (F7, W25, W30) and an hydrophobic side chain (L24). The high density in aromatic side chains of the putative functional surface as well as the lack of an asparagine is proposed to be the structural basis of the specificity of HpTX2 toward Kv4.2 channel.
Subject(s)
Neuropeptides/chemistry , Neurotoxins/chemistry , Potassium Channels, Voltage-Gated , Potassium Channels/chemistry , Spider Venoms/chemistry , Amino Acid Sequence , Animals , Anisotropy , CHO Cells , Charybdotoxin/chemistry , Conotoxins/chemistry , Cricetinae , Disulfides , Electrophysiology , Escherichia coli/metabolism , Lysine/chemistry , Magnetic Resonance Spectroscopy , Models, Molecular , Molecular Sequence Data , Protein Conformation , Protein Structure, Secondary , Recombinant Proteins/chemistry , Shal Potassium Channels , Time Factors , omega-Conotoxins/chemistryABSTRACT
Secondary brain lesions resulting from cerebral metabolic and hemodynamic reactions can be prevented by neurocritical care management. It must be initiated as soon as possible, ideally in a prehospital setting. Tracheal intubation, controlled ventilation and hemodynamic stabilization are the prerequisites. Beside intracranial and cerebral perfusion pressure, monitoring must evaluate the coupling between cerebral metabolic demand and blood flow. Jugular bulb oximetry is the most reliable approach to global cerebral coupling. Transcranial Doppler evaluates cerebral blood flow indirectly and noninvasively. Technological developments have led to local metabolic evaluation that does not yet have any clinical relevance. Therapeutic developments are more a new approach to the use of old drugs. Controlled hyperventilation, mannitol and, more recently, hypertonic saline solutions, used for restoring cerebral metabolic coupling, are the foundations of treatment. Thiopental, revisited as a vasoconstrictive agent, the "Lund" vasoconstrictive approach with anti-hypertensive drugs and cerebral vasoconstrictors, must be further evaluated in children, as must therapeutic hypothermia. Finally, what we probably need for the immediate future is a noninvasive and easily reproducible method of monitoring cerebral metabolic coupling that will allow precise therapeutic adaptation of multimodal therapy to the individual needs of the child.
Subject(s)
Brain Injuries/physiopathology , Brain Injuries/therapy , Critical Care/methods , Brain Injuries/metabolism , Cerebrovascular Circulation , Child , Craniocerebral Trauma/physiopathology , Craniocerebral Trauma/therapy , Humans , Hyperventilation , Monitoring, Physiologic/methods , Neuroprotective Agents/therapeutic use , Neurosurgical Procedures/methodsABSTRACT
The measurement of the middle ear transfer function usually requires invasive methods. An equivalent analog equivalent model enables us to evaluate its characteristics without damaging any part of the ear. A linear and a nonlinear model of the middle ear have been developed to predict intracochlear pressure and the stapes volume velocity for various sound pressure levels (SPL). The linear model results have been compared with human eardrum impedance and middle ear transfer function data. The nonlinear phenomena due to the contraction of the stapedius muscle over 80 dB and to the stapes clipping displacement above 120 dB are represented by a set of variable electrical components. The model of the acoustic reflex is based on experimental observations. The study of the annular ligament behavior was performed on cats and extrapolated to humans with some hypothetical restrictions. These approximations provide information on the middle ear transfer function and enable us to better understand the nonlinear middle ear mechanisms in an intense acoustic field.
Subject(s)
Ear, Middle/physiology , Humans , Models, Biological , Reflex, Acoustic/physiologyABSTRACT
cDNAs encoding novel long-chain scorpion toxins (64 amino acid residues, including only six cysteines) were isolated from cDNA libraries produced from the venom glands of the scorpions Androctonus australis from Old World and Tityus serrulatus from New World. The encoded peptides were very similar to a recently identified toxin from T. serrulatus, which is active against the voltage-sensitive 'delayed-rectifier' potassium channel, but they were completely different from the long-chain and short-chain scorpion toxins already characterised. However, there was some sequence similarity (42%) between these new toxins, Aa TX Kbeta and Ts TX Kbeta, and scorpion defensins purified from the hemolymph of Buthidae scorpions Leiurus quinquestriatus and A. australis. Thus, according to a multiple sequence alignment using CLUSTAL, these new toxins seem to be related to the scorpion defensins.
Subject(s)
Potassium Channels/drug effects , Scorpion Venoms/pharmacology , Toxins, Biological/pharmacology , Amino Acid Sequence , Base Sequence , DNA, Complementary , Disulfides/chemistry , Molecular Sequence Data , Scorpion Venoms/chemistry , Sequence Homology, Amino Acid , Toxins, Biological/chemistryABSTRACT
The resistance of the scorpion Androctonus australis to its own venom, as well as to the venom of other species, was investigated. A comparison of the electrical and pharmacological properties of muscle and nerve fibres from Androctonus australis with those from the crayfish Procambarus clarkii enabled us to understand the lack of effect of scorpion venom (110-180 microg ml-1) and purified toxins, which are active on voltage-gated Na+ and K+ channels, Ca2+-activated K+ channels, on scorpion tissues. Voltage-clamp experiments showed that peptide K+ channel blockers from scorpion and snake have no effect on currents in muscle and nerve fibres from either scorpions or crayfish. The scorpion toxin kaliotoxin (KTX), a specific blocker of Kv1.1 and Kv1.3 K+ channels, had no effect on muscle fibres of A. australis (2 micromol l-1) or P. clarkii (400 nmol l-1). Similarly, charybdotoxin (ChTX) had no effect on the muscle fibres of A. australis (10 micromol l-1) or P. clarkii (200 nmol l-1) and neither did the snake toxin dendrotoxin (DTX) at concentrations of 100 nmol l-1 in A. australis and 200 nmol l-1 in P. clarkii. These three toxins (KTX, ChTX and DTX) did not block K+ currents recorded from nerve fibres in P. clarkii. The pharmacology of the K+ channels in these two arthropods did not conform to that previously described for K+ channels in other species. Current-clamp experiments clearly indicated that the venom of A. australis (50 microg ml-1) had no effect on the shape of the action potential recorded from nerve cord axons from A. australis. At a concentration of 50 microg ml-1, A. australis venom greatly prolonged the action potential in the crayfish giant axon. The absence of any effect of the anti-mammal -toxin AaH II (100 nmol l-1) and the anti-insect toxin AaH IT1 (100 nmol l-1) on scorpion nerve fibres revealed strong pharmacological differences between the voltage-gated Na+ channels of scorpion and crayfish. We conclude that the venom from A. australis is pharmacologically inactive on K+ channels and on voltage-sensitive Na+ channels from this scorpion.
ABSTRACT
A cDNA encoding a short polypeptide blocker of K+ channels, kaliotoxin 2 (KTX2), from the venom of the North African scorpion Androctonus australis was expressed in the periplasmic space of Escherichia coli. KTX2 was produced as a fusion protein with the maltose binding protein followed by the recognition site for factor Xa or enterokinase preceding the first amino acid residue of the toxin. The fully refolded recombinant KTX2 (rKTX2) was obtained (0.15-0.30 mg/l of culture) and was indistinguishable from the native toxin according to chemical and biological criteria. An N-extended analogue of KTX2 exhibiting three additional residues was also expressed. This analogue had 1000-fold less affinity for the 125I-kaliotoxin binding site on rat brain synaptosomes than KTX2. Conformational models of KTX2 and its mutant were designed by amino acid replacement using the structure of agitoxin 2 from Leiurus quinquestriatus as template, to try to understand the decrease in affinity for the receptor.
Subject(s)
ATP-Binding Cassette Transporters , Escherichia coli Proteins , Monosaccharide Transport Proteins , Periplasmic Binding Proteins , Potassium Channel Blockers , Scorpion Venoms/metabolism , Amino Acid Sequence , Animals , Binding Sites , Carrier Proteins/genetics , Cloning, Molecular , Escherichia coli , Factor Xa/metabolism , Gene Expression , Genetic Vectors , Maltose-Binding Proteins , Models, Molecular , Molecular Sequence Data , Molecular Structure , Rats , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Scorpion Venoms/biosynthesis , Scorpion Venoms/chemistry , Scorpion Venoms/genetics , Scorpions , Sequence Homology, Amino Acid , Structure-Activity Relationship , Synaptosomes/metabolismABSTRACT
A single intron of 87 bp, close to the region encoding the C-terminal part of the signal peptide, was found in the gene of the 'short' scorpion toxin kaliotoxin 2 of Androctonus australis acting on various types of K+ channels. Its A+T content was particularly high (up to 86%). By walking and ligation-mediated PCR, the promoter sequences of the kaliotoxin 2 gene of Androctonus australis were studied. The transcription unit of the gene is 390 bp long. Consensus sequences were identified. The genes of 'short' scorpion toxins active on K+ channels are organized similarly to those of the 'long' scorpion toxins active on Na+ channels and not like those of structurally related insect defensins, which are intronless.